Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6)

Inclusion Criteria: * Confirmed diagnosis of metastatic soft-tissue or bone sarcoma * Ongoing complete response, partial response, or stable disease (RECIST) after a minimum of 4 cycles (and maximum of 12 months) of any one first, second, or third line of prior cytotoxic chemotherapy for metastatic disease * Eastern Cooperative Oncology Group performance status of 0 or 1 * Adequate organ and bone marrow function * Completed prior chemotherapy with last dose received at least 3 and up to 12 weeks prior to randomization Exclusion Criteria: * Prior therapy with rapamycin or rapamycin analogs * Ongoing toxicity associated with prior anticancer therapy * Another primary malignancy within the past three years * Concomitant medications that induce or inhibit CYP3A * Significant, uncontrolled cardiovascular disease